Lysergic acid diethylamide (LSD) is a hallucinogen, synthesised from ergot alkaloid, and controlled by the Misuse of Drugs Act (1971).

The regulation of a drug of abuse leads to the emergence of other compounds with partially altered structures, where, new and unregulated derivatives are developed to either improve upon their effects or bypass existing drug laws.

Lysergic acid diethylamide (LSD) analogs have appeared as designer drugs throughout the world. A study found that incubation of 1cP‐LSD with human serum led to the formation of LSD, indicating that it may act as a prodrug for LSD.

1cP-LSD appeared on the online research chemical market in 2019.

Limited data exist on the pharmacology, metabolism, and toxicity of 1cP-LSD. While it is presumed to have a similar risk profile as LSD and its analogs, which are generally thought to be safe in controlled settings, reliable scientific data is lacking. It is highly advised to use harm reduction practices if using this substance.

Anecdotal reports appear to support with this theory, with most users reporting near-identical effects as LSD. It has been reported to have a more gradual come up, along with mildly smoother cognitive and physical effects compared to LSD.